These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24145356)

  • 21. Survival after treatment of advanced renal cell carcinoma (RCC) with high-dose interleukin-2 (rIL-2) or vinblastine (VLB).
    Sorio R; Galligioni E; Crivellari D; Talamini R; Monfardini S
    Ann Oncol; 1995 Mar; 6(3):306-7. PubMed ID: 7612500
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase II study of oral ftorafur and uracil in patients with advanced renal cell carcinoma.
    Esteban E; Buesa JM; Cueva J; Fernández Y; Peláez I; Fernández JL; Sanz A; Palacio I; Estrada E; Gracia JM
    Eur J Cancer; 1993; 29A(9):1354. PubMed ID: 8343285
    [No Abstract]   [Full Text] [Related]  

  • 23. Tyrosine kinase inhibitors in renal cell cancer: Losing an empire and yet to find a role.
    Eisen T
    Eur J Cancer; 2015 Nov; 51(17):2578-9. PubMed ID: 26613659
    [No Abstract]   [Full Text] [Related]  

  • 24. Interferon plus vinblastine in renal carcinoma patients who had failed on interferon alone.
    Merimsky O; Chaitchik S
    Eur J Cancer; 1990; 26(8):921. PubMed ID: 2145941
    [No Abstract]   [Full Text] [Related]  

  • 25. Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?
    Halabi S; Rini BI; Escudier B; Stadler WM; Small EJ
    Cancer; 2015 Jun; 121(11):1906. PubMed ID: 25677867
    [No Abstract]   [Full Text] [Related]  

  • 26. Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?
    Becker A; Eichelberg C; Sun M
    Cancer; 2014 Jan; 120(1):7-10. PubMed ID: 24347382
    [No Abstract]   [Full Text] [Related]  

  • 27. Prolonged survival in renal transplant recipient with advanced renal cell carcinoma by everolimus and sorafenib.
    Ruangkanchanasetr P; Kanjanapayak B; Jungmeechoke K
    Nephrology (Carlton); 2011 Jan; 16(1):118-9. PubMed ID: 21175989
    [No Abstract]   [Full Text] [Related]  

  • 28. Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma.
    Nathan PD; Gore ME; Eisen TG
    J Clin Oncol; 2002 Mar; 20(5):1429-30. PubMed ID: 11870194
    [No Abstract]   [Full Text] [Related]  

  • 29. Combination of targeted agents in metastatic renal cell carcinoma: a path forward or a dead-end street?
    Michaelson MD
    Cancer; 2012 Apr; 118(7):1744-6. PubMed ID: 21898374
    [No Abstract]   [Full Text] [Related]  

  • 30. In focus: bevacizumab for renal cell carcinoma.
    Clin Adv Hematol Oncol; 2005 Jan; 3(1):68-9. PubMed ID: 16166971
    [No Abstract]   [Full Text] [Related]  

  • 31. Reply to progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?
    Becker A; Eichelberg C; Sun M
    Cancer; 2015 Jun; 121(11):1906-7. PubMed ID: 25677986
    [No Abstract]   [Full Text] [Related]  

  • 32. Experience gathered from retrospective series on renal cell carcinoma is useful, but now it is time for a global claim for academically driven prospective studies.
    Porta C; Paglino C
    Eur Urol; 2013 Jul; 64(1):71-2. PubMed ID: 23044174
    [No Abstract]   [Full Text] [Related]  

  • 33. Current and emerging first-line systemic therapies in clear cell renal cell carcinoma.
    Rini BI
    Clin Adv Hematol Oncol; 2018 Feb; 16(2):115-117. PubMed ID: 29741511
    [No Abstract]   [Full Text] [Related]  

  • 34. Genitourinary malignancies.
    Smith MR; Kantoff P
    Cancer Chemother Biol Response Modif; 1999; 18():394-417. PubMed ID: 10800495
    [No Abstract]   [Full Text] [Related]  

  • 35. Entropy increases in kidney cancer treatment, but a bit of simplicity may emerge from chaos.
    Porta C
    Eur Urol; 2011 Dec; 60(6):1171-2. PubMed ID: 21820238
    [No Abstract]   [Full Text] [Related]  

  • 36. Bevacizumab and everolimus in renal cancer: a rational way forward.
    Stadler WM; Phillips G; George DJ; Halabi S; Small E
    J Clin Oncol; 2010 Nov; 28(33):e692-3; author reply e694. PubMed ID: 20940194
    [No Abstract]   [Full Text] [Related]  

  • 37. Multiple drug resistance: biologic basis and clinical significance in renal-cell carcinoma.
    Chapman AE; Goldstein LJ
    Semin Oncol; 1995 Feb; 22(1):17-28. PubMed ID: 7855615
    [No Abstract]   [Full Text] [Related]  

  • 38. Prognostic factors in cytokine-refractory renal cell carcinoma treated with irinotecan, Cisplatin, and mitomycin chemotherapy.
    Shamash J; Powles T; Wilson P; Ansell W; Oliver T
    J Clin Oncol; 2005 Feb; 23(6):1323-5. PubMed ID: 15718335
    [No Abstract]   [Full Text] [Related]  

  • 39. New approaches to the evaluation of the metastatic ability of renal cancer and new approaches to chemotherapy.
    Isaacs WB; Isaacs JT; Kyprianou N; Burgers JK; Alexander RB; Partin AW; Mohler JL; Marshall FF; Coffey DS
    Eur Urol; 1990; 18 Suppl 2():33-5. PubMed ID: 2226604
    [No Abstract]   [Full Text] [Related]  

  • 40. [First-line therapy for German patients with metastatic kidney neoplasms in EORTC-Protocol 30012].
    Rexer H
    Urologe A; 2004 Aug; 43(8):992-3. PubMed ID: 15316609
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.